[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ventricular-tachycardia-monomorphic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ventricular-tachycardia-monomorphic":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,48,79,109],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100641935","cryoablation-for-monomorphic-ventricular-tachycardia-vts-100641935",false,"NCT07650032","Cryoablation for Monomorphic Ventricular Tachycardia (VTS)","Cryoablation for Monomorphic Ventricular Tachycardia IDE Study","FULCRUM-VT","Inclusion Criteria:\n\n* IC 1 Male or female ≥ 18 years\n* IC 2 Patients with a clinical indication for catheter ablation due to ischemic and\u002For non-ischemic heart disease and recurrent symptomatic sustained scar-mediated monomorphic Ventricular Tachycardia.\n* IC 3 Any of the following:\n\n  * Ischemic cardiomyopapthy (ICM) patients with prior history of myocardial infarction with Q waves, focal wall motion abnormality on imaging, fixed perfusion defect correlating with coronary stenosis or prior coronary intervention, 20% ≤ LVEF \\\u003C 50%.\n  * non-ischemic cardiomyopathy (NICM) patients with scar in a territory without coronary stenosis as evidenced by CMR imaging within the prior 90 days or intra-procedurally using EAM and PES prior to investigational device use, 20% ≤ LVEF \\\u003C 50%\n  * Arrhythmogenic right ventricular cardiomyopathy (ARVC)\n* IC 4 Has received a market-released ICD prior to enrollment\n* IC 5 Patient has had at least 1 documented spontaneous episode of SMVT within the previous 6 months\n* IC 6 Refractory to, or intolerant of, at least one Class III AAD. (Refractory or intolerant defined as AAD failure due to recurrent VT, not tolerated\u002F desired due to side effects)\n* IC 7 Willingness, ability, and commitment to participate in baseline and follow-up evaluations for the full length of the study\n* IC 8 Willingness and ability to give an informed consent\n\nExclusion Criteria:\n\n* EC 1 Intracardiac thrombus by TTE or TEE within 48 hours prior to the procedure\n* EC 2 Presence of isolated epicardial scar(s) requiring epicardial ablation identified by either preoperative CMR imaging within 90 days of procedure or intra-procedurally using EAM and PES prior to investigational device use\n* EC 3 VTs due to any of the following causes:\n\n  1. Idiopathic VT\n  2. Automaticity or triggered activity\n  3. Bundle Branch Reentry (BBR)\n  4. Any focal tachycardia (e.g., papillary, RVOT)\n  5. Ventricular tachycardia secondary to electrolyte imbalance, active thyroid disease, or any other reversible or non-cardiac cause\n* EC 4 NICM patients only, if any of the following apply:\n\n  1. Congenital condition that limits access to the left or right ventricles\n  2. Severe aortic or mitral stenosis, severe mitral regurgitation, or severe aortic insufficiency\n  3. Active inflammatory processes (e.g., myocarditis) within the past 120 days\n  4. Sarcoidosis\n  5. Hypertrophic cardiomyopathy\n  6. Drug- or alcohol-induced cardiomyopathy\n* EC 5 Any VT ablation within 4 weeks prior to enrollment\n* EC 6 More than one prior (\\>4 weeks) VT ablation or prior surgical treatment for VT within the past 2 years\n* EC 7 Cardiogenic shock, unless it is due to incessant monomorphic VT\n* EC 8 Any other cardiovascular conditions as described below:\n\n  1. Class IV heart failure\n  2. Aortic aneurysm\n  3. Previous cardiac surgery or percutaneous coronary intervention within 60 days prior to index procedure\n  4. Interatrial baffle, closure device, patch, or PFO occlusion device\n  5. Coronary artery bypass graft (CABG) procedure within six (6) months prior to the ablation procedure\n  6. Acute MI or unstable angina in the previous 60 days\n  7. Mechanical mitral or aortic valve\n  8. Cardiac myxoma\n  9. Significant congenital heart disease\n* EC 9 Acute illness or active systemic infection\n* EC 10 Any previous history of cryoglobulinemia\n* EC 11 History of blood clotting or bleeding disease\n* EC 12 Peripheral vascular disease that precludes LV access\n* EC 13 Contraindication to heparin\n* EC 14 Allergy to radiographic contrast dye that cannot be medically managed prior to the ablation procedure\n* EC 15 Any prior history of documented cerebral vascular accident (CVA), TIA or systemic embolism (excluding a post-operative Deep Vein Thrombosis, DVT), within 6 months prior to the ablation procedure.\n* EC 16 Pregnant, or anticipated pregnancy during study follow-up\n* EC 17 Current enrollment in any other study protocol where testing or results from that study may interfere with the procedure or outcome measurements for this study\n* EC 18 Any other condition (e.g., ARVC with extensive free wall scarring) that, in the judgment of the investigator, makes the patient a poor candidate for this procedure, the study or compliance with the protocol (includes vulnerable patient population, mental illness, addictive disease, candidate for heart transplantation, patient with ventricular assist device, or terminal illness with a life expectancy less than 12 months)","ALL","18 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"NA","The objective of this clinical study is to evaluate the safety and effectiveness of the Adagio Medical vCLAS Ventricular Ablation System (including VTS Catheter and Console) in the ablation treatment of Sustained Monomorphic Ventricular Tachycardia (SMVT)",[27,28],"Ventricular Tachycardia, Sustained","Ventricular Tachycardia, Monomorphic",[30,31,32,33,34],"cryoablation","monomorphic VT","sustained monomorphic VT","Ultra Low Temperature Ablation","ULTA","NOT_YET_RECRUITING","2026-06-15",{"date":38,"type":39},"2026-06-17","ACTUAL",{"date":41,"type":21},"2026-08-01",{"date":43,"type":21},"2027-09-30",{"name":45,"class":46},"Adagio Medical","INDUSTRY",10,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":78},"100640189","stereotactic-radioablation-as-first-line-therapy-for-scar-related-ventricular-tachycardia-100640189","NCT07618780","Stereotactic Radioablation as First-Line Therapy for Scar-Related Ventricular Tachycardia","Stereotactic Arrhythmia Radioablation as First-Line Treatment for Scar-Related Ventricular Tachycardia","START-VT","Inclusion Criteria:\n\n* Age 18 years or older and able to provide informed consent\n* Structural heart disease with myocardial fibrosis identified on pre-procedural imaging, including imaging evidence of regional myocardial akinesis\u002Fthinning or documented scar on echocardiography, cardiac CT, or cardiac MRI\n* Sustained monomorphic ventricular tachycardia (symptomatic or requiring ICD shocks for termination) within the previous 6 months\n\nExclusion Criteria:\n\n* Reversible causes of VT (e.g., active ischemia, drug-induced, electrolyte abnormalities)\n* Acute coronary syndrome within 30 days, coronary revascularization (\\\u003C90 days for bypass surgery, \\\u003C30 days for percutaneous coronary intervention)\n* Patients previously treated with high-dose radiotherapy that precludes safe delivery of thoracic stereotactic radiotherapy (relative contraindication)\n* Patients requiring chest radiotherapy for an active cancer (relative contraindication)\n* VT targets cannot be identified or are not suitable for targeting with stereotactic radiotherapy (such as multiple foci of arrhythmia)\n* Patients who cannot tolerate the radiotherapy treatment position, or whose body habitus is not permissible by treatment bed requirements\n* Pregnant or breast-feeding women\n* Patients being considered for cardiac transplant who are deemed not eligible by their transplant team for STAR",{"count":57,"type":21},20,[24],"Ventricular tachycardia (VT) is a dangerous fast heart rhythm originating from scarred areas of the heart muscle, often after a heart attack or in patients with cardiomyopathy. Patients with VT and structural heart disease typically receive an implantable cardioverter-defibrillator (ICD) to prevent sudden death. Despite the ICD, recurrent VT and ICD shocks remain common and are associated with poor quality of life. Current preventive therapies - antiarrhythmic medications and catheter radiofrequency ablation - have important limitations including side effects, incomplete effectiveness, and procedural risk.\n\nStereotactic Arrhythmia Radioablation (STAR) is a non-invasive treatment in which a single, precisely targeted dose of radiation is delivered to the scar tissue that gives rise to the abnormal heart rhythm. STAR has previously been studied in patients who have failed catheter ablation or are too high risk for that procedure, with promising results. However, STAR has not been formally evaluated as a first-line treatment.\n\nThis single-arm prospective feasibility study will enroll 20 adults with structural heart disease and sustained monomorphic VT. Each participant will receive a single 25 Gy fraction of stereotactic body radiotherapy (VMAT technique) targeted at the arrhythmogenic substrate identified by cardiac imaging, 12-lead ECG, and (where available) non-invasive electrocardiographic mapping or electroanatomical mapping. Participants will be followed at 6 weeks, 3, 6, 9, and 12 months to assess the primary efficacy outcomes (death, appropriate ICD shock, VT storm, and sustained VT below ICD detection rate after a 6-week blanking period) and safety outcomes (acute heart failure decompensation, drop in left ventricular ejection fraction, and STAR-specific toxicities such as pneumonitis, esophagitis, and pericarditis). The hypothesis is that STAR delivered as first-line therapy is safe and effective, with a comparable toxicity and efficacy profile to catheter radiofrequency ablation.",[28,61],"Cardiomyopathies",[63,64,65,66,67],"Stereotactic Body Radiotherapy","Cardiac Radioablation","Radioablation","Implantable Cardioverter Defibrillator","STAR-VT","2026-05-24",{"date":70,"type":39},"2026-06-01",{"date":72,"type":21},"2026-07",{"date":74,"type":21},"2029-07",{"name":76,"class":77},"Southlake Health","OTHER",1,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":22,"phases":88,"briefSummary":89,"conditions":90,"keywords":93,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":78},"100588182","imaging-and-treatment-planning-for-cardiac-radioablation-100588182","NCT06938074","Imaging and Treatment Planning for Cardiac Radioablation","ITPCR","Inclusion Criteria\n\n* Ischemic cardiomyopathy with monomorphic VT\n* Referred by cardiologists\n* 18 years of age or older Exclusion Criteria\n* • Polymorphic ventricular tachycardia\n* Ventricular fibrillation\n* Pregnant or breastfeeding or planning to become pregnant or breastfeed during the study\n* Estimated glomerular filtration rate ≤ 30 mL\u002Fmin\u002F1.73m2\n* Previous allergic reaction to CT contrast agent Note that participants with contraindications for MRI can still be enrolled in this study but will not undergo MRI parts of this protocol.",{"count":87,"type":21},15,[24],"Cardiac radioablation is a new treatment for ventricular tachycardia (VT), which uses beams of radiation to treat heart scar that causes VT. To identify the scar areas, magnetic resonance imaging (MRI) and computed tomography (CT) imaging are often used. These are both types of medical imaging that allow clinicians to examine scar area without having to do invasive surgery.\n\nResearchers have developed new heart imaging protocols using both MRI and CT. Their MRI protocol method can now spot both dense and scattered scar tissue. The CT protocol combines multiple different types of scans into a single appointment and uses a special scanner that captures the motion of the heart. For this study, patients will undergo CT and MRI imaging according to these new imaging protocols.\n\nWith this study, researchers aim to show that these new imaging protocols can be undergone by patients with ventricular tachycardia and can be used to identify scar. Researchers will also use these scans to make radiation treatment plans to identify which types of treatment can be delivered safely to patients.",[28,91,92],"Ventricular Tachycardia (V-Tach)","Ischemia, Myocardial",[94,95,96,97,98,99],"Cardiac radioablation","Stereotactic arrhythmia radioablation","Ischemic fibrosis","Late iodine enhancement CT","CT perfusion","Late gadolinium enhanced MRI","2025-09-22",{"date":102,"type":39},"2025-09-26",{"date":104,"type":21},"2025-11-01",{"date":106,"type":21},"2026-09-01",{"name":108,"class":77},"Stewart Gaede",{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":22,"phases":118,"briefSummary":119,"conditions":120,"keywords":126,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":78},"100594316","stereotactic-radiosurgery-as-second-line-therapy-for-ventricular-tachycardia-100594316","NCT07017855","Stereotactic Radiosurgery as Second-line Therapy for Ventricular Tachycardia","STAR-4VT","Inclusion Criteria:\n\n1. Age ≥ 18 years at the time of enrollment.\n2. Presence of structural heart disease (SHD) of either ischemic or non-ischemic etiology.\n3. Implanted ICD or CRT-D device for primary or secondary prevention of sudden cardiac death (SCD).\n4. History of at least one endocardial CA procedure targeting a substrate of monomorphic sVT.\n5. Recurrence of at least one clinically significant and symptomatic episode of monomorphic sVT.\n6. Optimal pharmacological treatment of underlying SHD, including maximally tolerated doses of guideline-recommended heart failure therapies and appropriate antiarrhythmic management.\n7. Provision of written informed consent prior to study participation.\n\nExclusion Criteria:\n\n1. Reversible cause of sVT recurrence, particularly acute coronary syndrome (ACS), acute myocarditis, or lead-related infective endocarditis (LDIE).\n2. Myocardial infarction (MI) or cardiac surgery within the last 40 days.\n3. Idiopathic sVT unrelated to SHD or sVT associated with genetically determined channelopathies.\n4. Ongoing or persistently recurrent hemodynamically unstable sVT until clinical stabilization is achieved.\n5. Acute decompensation of heart failure, classified as New York Heart Association (NYHA) Class IV, until clinical stabilization is achieved.\n6. Worsening angina, classified as Canadian Cardiovascular Society (CCS) Class III or IV until coronary diagnostic evaluation and clinical stabilization are completed.\n7. A mobile thrombus within the left ventricle (LV).\n8. Presence of a left ventricular assist device (LVAD).\n9. Presence of comorbidities or known risk factors for CA complications that, in the judgment of the electrophysiologist, constitute a contraindication to the procedure for safety reasons.\n10. Active, uncontrolled malignancy and\u002For chemotherapy or immunotherapy administered or planned within 1 month of the scheduled ablation procedure.\n11. Features of an active systemic, pulmonary, or pericardial inflammatory process requiring systemic treatment (disease-modifying therapies, corticosteroids, immunosuppressants) within the past 6 months.\n12. Presence of comorbidities or known risk factors for radiotherapy complications that, in the judgment of the radiation oncologist, constitute a contraindication to STAR for safety reasons.\n13. Pregnancy or breastfeeding.\n14. Systemic disease that limits the probability of survival to less than 1 year\n15. Other comorbidities, addictions, or social indications that, in the investigator's opinion, would preclude practical cooperation or otherwise disqualify the patient from participation in the clinical study.\n16. Refusal to participate or lack of written informed consent for study participation.",{"count":117,"type":21},150,[24],"The aim of the study is to compare the efficacy and safety of treating recurrent sustained Ventricular Tachycardia (sVT) after prior Catheter Ablation (CA) in patients with Implanted Cardioverter-Defibrillator (ICD) between re-do of conventional endocardial CA and Stereotactic Arrhythmia Radioablation (STAR).",[28,27,121,91,122,123,124,125],"Ventricular Tachycardia (VT)","Stereotactic Body Radiation Therapy (SBRT)","Stereotactic Techniques","Stereotactic Radiation","Cardioverter-Defibrillators, Implantable",[127,128,129,130,131,132],"Ventricular Tachycardia","VT","Stereotactic Arrhythmia Radioablation","STAR","Implanted Cardioverter-Defibrillator","ICD","2025-06-04",{"date":135,"type":39},"2025-06-12",{"date":137,"type":21},"2025-07-01",{"date":139,"type":21},"2028-11-01",{"name":141,"class":77},"Medical University of Silesia"]